A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-Hematologic Malignancy.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Linifanib (Primary) ; Erlotinib
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
- 28 Jan 2009 Actual initiation date (Sep 2008) added as reported by ClinicalTrials.gov.
- 28 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 28 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 28-1-2009.